This news is delayed by 15 minutes, sign up now to get live news & full features.
LENZ LENZ THERAPEUTICS INC
+ add to watchlist
$19.39
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives
Mkt Cap: $553.04M
52 Week High: $50.40
P/E: 0.00
52 Week Low: $14.43
Dividend: $0.00
Shares Outstanding: 28.52M